{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T12:26:20Z","timestamp":1766579180467,"version":"3.43.0"},"reference-count":21,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ocular surface disorders have been reported among patients with various medical conditions, including atopic dermatitis (AD). Nonetheless, validated algorithms to identify conjunctivitis and keratitis in claims data are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Develop validated, claims\u2010based algorithms for conjunctivitis and keratitis among patients with AD using medical records.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with AD were identified in a claims database between March 2017 and November 2019. Among these patients, candidate algorithms were developed that included diagnosis codes for conjunctivitis or keratitis, alone and in combination with ophthalmic treatments. Among patients who met \u2265\u20091 candidate algorithms, a subset was randomly selected for medical record review. Additionally, records from a random sample of patients with AD were reviewed to assess sensitivity. Overall, 341 records were sought and 262 adjudicated by an expert ophthalmologist. The positive predictive value (PPV) of each algorithm was calculated and compared to a pre\u2010specified threshold of \u2265\u200970%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For conjunctivitis, the final algorithm was \u2265\u20091 conjunctivitis diagnosis (PPV\u2009=\u200981%, 95% confidence interval [CI]: 73%\u201387%). For keratitis, the final algorithm combined the following 2 candidate algorithms: \u2265\u20091 keratitis diagnosis and \u2265\u20091 dispensing of a topical antibiotic or antibiotic\u2013steroid combination (PPV\u2009=\u200991%); and \u2265\u20091 keratitis diagnosis and \u2265\u20091 dispensing of an ophthalmic corticosteroid, topical immune\u2010modulator, or topical NSAID (PPV\u2009=\u200968%) for an overall PPV of 80% (95% CI: 55%\u201393%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The first claims\u2010based algorithms to identify conjunctivitis and keratitis among AD patients were developed and validated. They are available for use in future studies, particularly to better understand conjunctivitis and keratitis occurrence among patients with AD.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.70052","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T12:07:55Z","timestamp":1731499675000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development and Validation of Claims\u2010Based Algorithms for Conjunctivitis and Keratitis"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-1446","authenticated-orcid":false,"given":"Andrea K.","family":"Chomistek","sequence":"first","affiliation":[{"name":"Optum Epidemiology  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8941-4116","authenticated-orcid":false,"given":"Jessica M.","family":"Franklin","sequence":"additional","affiliation":[{"name":"Optum Epidemiology  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel E.","family":"Sobel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea F.","family":"Marcus","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah\u2010Jo","family":"Sinnott","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ezzy","sequence":"additional","affiliation":[{"name":"Optum Epidemiology  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert V.","family":"Gately","sequence":"additional","affiliation":[{"name":"Optum Epidemiology  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannette","family":"Green","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Howell","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ihtisham","family":"Sultan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esen K.","family":"Akpek","sequence":"additional","affiliation":[{"name":"Johns Hopkins University  Baltimore Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-9434","authenticated-orcid":false,"given":"Florence T.","family":"Wang","sequence":"additional","affiliation":[{"name":"Optum Epidemiology  Boston Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S233486"},{"issue":"45","key":"e_1_2_10_3_1","first-page":"1027","article-title":"Estimated Burden of Keratitis\u2014United States, 2010","volume":"63","author":"Collier S. A.","year":"2014","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.10.020"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.11.037"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.084"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000843"},{"key":"e_1_2_10_9_1","unstructured":"United States Food and Drug Administration \u201cGuidance for Industry and FDA Staff: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data \u201d(2013)."},{"volume-title":"Epidemiology: An Introduction","year":"2002","author":"Rothman K. J.","key":"e_1_2_10_10_1"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2317"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5229"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.06.104"},{"volume-title":"Conjunctivitis Among Individuals With Moderate\u2010To\u2010Severe Atopic Dermatitis Treated With Dupilumab in the United States","year":"2024","author":"Franklin J. M.","key":"e_1_2_10_14_1"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.4394"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-2-3"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2259-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02435-y"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-020-0403-9"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.028"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.03.011"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac116"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T03:42:01Z","timestamp":1738035721000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1002\/pds.70052"],"URL":"https:\/\/doi.org\/10.1002\/pds.70052","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70052"}}